The Role of Social and Territorial Inequalities in the Management and Prognosis of Multiple Sclerosis
NCT ID: NCT05017038
Last Updated: 2021-08-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
2000 participants
OBSERVATIONAL
2021-03-03
2023-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In addition to social inequalities, which refer to disparities in health levels according to social category, there are the effects of territorial inequalities. In France, there are geographical areas of excess mortality, which essentially correspond to areas far from urban centers. Similarly, there are major geographical differences in terms of medical supply and equipment, and the distance between patients and health centers is a direct obstacle to the use of the health care network.
The underlying explanations for social inequalities in health are multiple. While it is likely that difficulties in accessing and using care play a role, it is also possible that they are due to differences in exposure to certain environmental (e.g. pollution) or individual (e.g. smoking) risk factors. But it is also possible that the causal relationship is the opposite and that diseases create or reveal social inequalities.
For multiple sclerosis (MS) the impact of social and territorial inequalities is more debated. Indeed, with regard to the relationship between disease prevalence and social inequalities, a recent literature review found 21 separate studies on the subject, of which 13 failed to show a link between socioeconomic status and MS risk, 5 concluded that there was an increased risk of MS in advantaged populations and 3 concluded that there was an increased risk of MS in disadvantaged populations. There are plausible pathophysiological explanations for either direction of the relationship, but the question remains open.
To our knowledge, the link between MS prognosis and social inequalities has been little studied, as disadvantaged populations are more often exposed to the poor prognostic factor of smoking \[6-8\], the hypothesis of a negative prognostic role of social inequalities remains plausible. Similarly, the current consensus is that the diagnosis and treatment of MS should be as early as possible \[9,10\] in order to preserve brain capital. Easy access to a neurologist and MRI are therefore potentially prognostic factors for MS in relation to territorial inequalities. It should be noted that the link between social and geographical inequalities and a potential delay in treatment has not been demonstrated in France in the case of cancer, but it is possible that the importance of the means implemented in the fight against cancer erases these effects. In MS, a study showed a link between delay in starting a second disease-modifying therapy and socio-economic status.
While the causal link between MS and socio-professional status has not yet been demonstrated, the socio-economic impact of MS has been measured. In particular, it has been shown that having MS is associated with an increased risk of unemployment and/or early retirement.
The primary objective of our study is to determine whether delay in treatment, as a marker of difficulties in access to care in MS, is associated with social and territorial inequalities in MS. Secondary objectives will be to explore the link between MS prognosis and social and territorial inequalities.
Exposure to sunlight is a known protective factor and is consistent with the north-east-south-west gradient observed in France. The choice of centers associated with the research, spread over the French territory, will make it possible to monitor and measure this effect in the prognosis of MS.
As the available treatments have evolved considerably over the last ten years, and in order to avoid a period effect, the patients recruited in the study will have to have a date of onset of the disease after 1 January 2009.
Primary objective Determining the relationship between socio-economic inequalities and the time to start disease-modifying therapy in MS Secondary objective
1. To determine the relationship between geographical inequalities and delay in starting disease-modifying therapy in MS
2. To determine the relationship between socio-economic inequalities and time to walking disability (EDSS 4)
3. To determine the relationship between geographical inequalities and time to walking disability (EDSS 4)
4. To measure the impact of disability on socioeconomic status in MS patients
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Influence of Socio-Economic Factor on Net Survival in Patients With Multiple Sclerosis in France ( ECOVIMUS).
NCT04028232
Cognitive Disability and Quality of Life of Patients Suffering From Multiple Sclerosis and Treatment With Immunosuppressant
NCT01392872
Impact of the Modifications of Environmental Exposures and Health Care Access During COVID-19 Lockdown on Multiple Sclerosis
NCT05033782
Disability, Perceived Social Support and Quality of Life in Multiple Sclerosis
NCT02880553
Study of Empathy in MS
NCT05332951
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have a confirmed MS according to the McDonald criteria 2017
* Have the date of onset of the disease recorded in EDMUS
* Have a disease onset date after 1 January 2009
* For patients receiving treatment for their MS\*: have the date of first disease- modifying therapy entered in EDMUS
* Patients not receiving treatment for their MS can be included if they meet the other criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Central Hospital, Nancy, France
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marc DEBOUVERIE, PU-PH
Role: PRINCIPAL_INVESTIGATOR
Service de Neurologie CHRU de Nancy
Aurélie RUET, PU-PH
Role: PRINCIPAL_INVESTIGATOR
Service de Neurologie et Maladies inflammatoires du systéme nerveux central
Gilles EDAN, PU-PH
Role: PRINCIPAL_INVESTIGATOR
PÔLE NEUROSCIENCES, CHU de Rennes
Pierre CLAVELOU, PU-PH
Role: PRINCIPAL_INVESTIGATOR
Service de Neurologie, CHU de Clermont-Ferrand
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Service de Neurologie et Maladies inflammatoires du Système nerveux central
Bordeaux, , France
Service de Neurologie
Clermont-Ferrand, , France
Service de Neurologie
Nancy, , France
Pôle Neurosciences
Rennes, , France
CIC 1433 Épidémiologie CliniqueInserm, CHRU, Université de Lorraine
Vandœuvre-lès-Nancy, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2019-A02739-48
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.